Clinical Trial Update: Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial of simtuzumab with FOLFIRI as second-line therapy in colorectal adenocarcinoma has terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Simtuzumab (simtuzumab)

Snippet

Sponsor: Gilead Sciences | Conditions: Colorectal Cancer | Phase 2 | Status: TERMINATED | Results posted: 2019-04-17